诺和诺德：CagriSema在减重和糖化血红蛋白降低两方面优于司美格鲁肽

Core Insights - Novo Nordisk announced the core results of the Phase 3 trial REIMAGINE 2 from its global REIMAGINE clinical trial program, demonstrating that CagriSema outperformed semaglutide in reducing hemoglobin A1c levels and weight loss at week 68 [1] Group 1 - CagriSema showed superior efficacy in both weight loss and reduction of hemoglobin A1c levels compared to single-component medications [1] - The safety and tolerability of CagriSema were found to be good, consistent with the characteristics of therapies based on incretin and insulin [1]